NASDAQ: MAZE Maze Therapeutics, Inc. 10-Q

Maze reports $20M Shionogi milestone, positive MZE829 data, and $185M in new capital

Filed May 12, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 14, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade MAZE commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.